Search results
Showing 3501 to 3550 of 3761 results for treatment
other options for maintaining remission. Toavoid unnecessarily changing treatments for people who started taking biologics before...
Discontinued Reference number: GID-TA11339
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
What is the clinical and cost effectiveness of opioids for the management of acute sciatica?
clinical benefit. It might lead to an increased use of other recommended treatments. Full details of the evidence and the committee's...
What is the clinical and cost effectiveness of antidepressants for the management of sciatica?
clinical benefit. It might lead to an increased use of other recommended treatments. Full details of the evidence and the committee's...
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Discontinued Reference number: GID-TA10702
In development Reference number: GID-TA11251 Expected publication date: TBC
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Hundreds could benefit from life saving blood cancer treatment recommended by NICE
People with a rare and aggressive blood cancer will benefit from a potentially life saving treatment, following NICE’s recommendation of a CAR-T (chimeric antigen receptor T-cell) treatment developed by a British spinout company.
In development Reference number: GID-TA11274 Expected publication date: TBC
Biographies for all current members of the diagnostics advisory committee.
Biographies for all current members of the diagnostics advisory committee.
Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)
Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
The appraisal has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
Discontinued Reference number: GID-TA10566
Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development Reference number: GID-TA11086 Expected publication date: TBC
Newly recommended CBT therapies could help children and young people deal with anxiety
NICE conditionally recommends digital cognitive behaviour therapies (CBT) for use in the NHS to help children and young people with symptoms of mild to moderate anxiety
The Arrow OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy (MIB19)
NICE has developed a Medtech Innovation Briefing (MIB) on the ARROW OnControl powered bone marrow biopsy system for bone marrow aspiration and biopsy
The government has today (1 December 2025) announced that it will increase the thresholds NICE uses in evaluations of new medicines to decide which are cost-effective for use in the NHS.
Seven digital platforms supporting at home cardiac rehab given conditional recommendations
People with heart disease will be able to do their recovery sessions from home rather than travelling for rehabilitation appointments after our independent committee conditionally recommended 7 digital platforms for use in the NHS.
Learn how NICE healthtech guidance helped East London NHS Foundation Trust tackle rising demand for children's mental health services.
This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together and provide more coordinated support to children and young people, and their families and carers.
Show all sections
Sections for NG213
- Overview
- Recommendations on support for all disabled children and young people with severe complex needs
- Recommendations on specialist support for disabled children and young people with particular needs
- Recommendations on service organisation, integration and commissioning
- Terms used in this guideline
- Recommendations for research
- Rationale and impact for recommendations on supporting all disabled children and young people with severe complex needs
- Rationale and impact for recommendations on specialist support for disabled children and young people with particular needs
Fertility clinics must end unproven treatments that don't help couples have babies
Fertility clinics should not offer unproven treatments that do not help people have babies, our independent committee has recommended in draft guidance.
Accelerating innovation: How NICE is opening pathways to digital health technologies for the NHS
Following her appearance at this year’s HETT Show, programme director Sarah Byron tells us why the government’s 10 Year Plan is a game changer for healthtech and how we’re driving the changes at NICE.
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
For more than 25 years NICE has helped practitioners and commissioners get the best care to people, fast, while ensuring value for the taxpayer.
People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.
Learn about our role in the new international Health Economics Methods Advisory (HEMA) and its ambitions to make a real difference to patients around the world.
Pre-exposure prophylaxis (PrEP) became routinely available through sexual health clinics in 2020, with NICE recommending the tablets for people at high risk of HIV in 2021.
First HIV prevention injection for people unable to have daily PrEP recommended
A ground-breaking HIV-1 prevention injection has been recommended by NICE, marking a significant advance for a small group of adults and young people unable to have daily pre-exposure prophylaxis (PrEP) tablets.
We explore the ongoing debate around NICE’s cost-effectiveness thresholds and what the future holds.
Tackling variation in rehab for people with neurological conditions
NICE has recommended a standardised approach for rehabilitation, to address the variation of care experienced by millions of people with chronic neurological conditions.
Our chief executive, Dr Sam Roberts, welcomes the government's 10 Year Plan for healthcare
The government's 10 Year Plan marks a pivotal moment for healthcare and strengthens NICE’s role.
NICE joins international collaboration on HTA methods research
We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.
Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery
New guidance aims to reduce variation in treatment and prevent unnecessary surgery, improving care for patients and supporting healthcare professionals.
NICE has been working in partnership with the London School of Economics and Political Science (LSE) to jointly develop and deliver an Executive MSc in Healthcare Decision-Making. Discover how this advanced healthcare training bridges clinical practice and system-wide decision-making through one committee member's transformative journey.
The new approach puts HealthTech on equal footing with medicines, ensuring innovations like wearable diabetes monitors and AI diagnostics reach patients faster and more consistently across the NHS.
Hundreds of people set to benefit after life-extending lung cancer treatment given green light
Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE.
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.
Biggest shake-up in type 2 diabetes care in a decade announced
Millions of people are set to benefit from earlier access to newer type 2 diabetes treatments – the biggest shake-up in care for a decade – as part of NICE’s commitment to re-evaluate priority clinical pathways described in the 10-Year Health Plan for the NHS.
Recommendations in NICE’s type 2 diabetes guideline update, published today, will enhance the use of SGLT-2 inhibitors in primary care and address these health inequalities.
People coming off obesity medication or finishing a weight management programme should be offered support to help keep the weight off and stay healthy long-term, according to our updated quality standard.